Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for 

. He is also the executive producer of two podcasts: 

. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

HCPLive is providing on-site coverage of the 2026 Fall Clinical Dermatology Conference, held October 8 to 11 at the Wynn Las Vegas, featuring expert-led therapeutic updates and interviews with dermatology leaders.¹,²

Now in its 46th year, the meeting is chaired by April W. Armstrong, MD, MPH; James Q. Del Rosso, DO; Seemal R. Desai, MD; Gary Goldenberg, MD; Mark Lebwohl, MD; Mark S. Nestor, MD, PhD; Darrell S. Rigel, MD, MS; and Linda F. Stein Gold, MD.² It offers up to 24.25 

™ through the joint providership of the University of Nevada, Reno School of Medicine and CMEsquared.²

Over the course of this 4-day meeting, dermatologists, researchers, and other skin health professionals will convene to review new data, practical treatment strategies, and evolving approaches across medical, surgical, and aesthetic dermatology.

What to Expect at Fall Clinical 2026 in Las Vegas:

This year’s program features symposia, focused seminars, and rapid-fire DermDash sessions. Topics span atopic dermatitis, psoriasis, hidradenitis suppurativa, vitiligo, alopecia areata, chronic spontaneous urticaria, skin cancer, and the growing role of artificial intelligence (AI) in dermatology practice.²

 will be on-site throughout the conference, providing exclusive interviews with dermatology leaders, coverage of notable sessions, and reporting on the latest clinical insights shared during the meeting.

 Hamzavi and Abrar A. Qureshi, MD, MPH, examine the evolving role of Janus kinase (JAK) inhibition in vitiligo (Thursday, October 8)

Nonsteroidal topicals in atopic dermatitis: Brad P. Glick, DO, MPH, and Stein Gold discuss individualizing topical therapy as nonsteroidal options expand (Thursday, October 8)

Glick and Lebwohl share head-to-head insights on interleukin (IL)-17 inhibitors (Friday, October 9)

 Shawn Kwatra, MD, and Michelle Tarbox, MD, present case-based management in the era of targeted therapies (Saturday, October 10).

Trotter and Todd E. Schlesinger, MD, offer a deep dive on the disease and the latest in immunotherapy (Saturday, October 10)

 Christopher G. Bunick, MD, PhD, presents case-based approaches for daily practice (Thursday, October 8)

 Naiem T. Issa, MD, PhD, reviews KIT-targeted approaches (Thursday, October 8)

Henry W. Lim, MD, and Rigel ask whether bemotrizinol changes which sunscreen clinicians recommend (Friday, October 9)

Among the many sessions on this year’s agenda, the following offer practical updates for clinicians attending the conference.

What Have We Learned About Skin of Color? What Can We Use To Improve Outcomes?

Thursday, October 8 • 9:35–9:50 AM PDT • Bandol

Andrew F. Alexis, MD, MPH, and Tiffany Mayo, MD, MSc, will review lessons learned in skin of color dermatology and the tools clinicians can use to improve outcomes for patients with skin of color.

When to Start, When to Switch: Positioning JAK Inhibitors in Atopic Dermatitis Management

Thursday, October 8 • 9:50–10:35 AM PDT • Bandol

This satellite symposium will address evidence-based use of JAK inhibitors in atopic dermatitis following inadequate response, as well as how to counsel patients about safety and treatment expectations. Faculty include Bunick, Diego Ruiz Dasilva, MD, and Ruth Ann Vleugels, MD, MPH, MBA.

The Next Chapter in Psoriasis Therapy: The Role of New and Emerging TYK2 Inhibitors

Thursday, October 8 • 2:05–2:50 PM PDT • Bandol

Speakers will discuss how to incorporate treat-to-target benchmarks into psoriasis treatment plans. They will also cover how selective tyrosine kinase 2 (TYK2) inhibition differs from broader JAK inhibition, and where new and emerging TYK2 inhibitors may fit in optimizing disease control. Faculty include Edward (Ted) Lain, MD, MBA; Stein Gold; and Ronald Vender, MD.

Oral Psoriasis Therapies: A Brighter Horizon

Friday, October 9 • 10:25–11:10 AM PDT • Cristal 2, 4, & 6

Armstrong, Tina Bhutani, MD, and Song will explore the potential of oral therapies to fill unmet needs in psoriasis care. They will also provide clinical updates on emerging and approved oral agents and discuss incorporating these agents into patient-centered treatment planning.

Better Biologic Decision-Making for Moderate-to-Severe Atopic Dermatitis: An Interactive Expert Exchange

Friday, October 9 • 11:30 AM–12:15 PM PDT • Cristal 2, 4, & 6

Armstrong, Chovatiya, and Elizabeth (Lisa) A. Swanson, MD, will discuss when to escalate therapy and how to differentiate biologics for individualized treatment selection. They will also share strategies for strengthening patient and caregiver communication to support lasting adherence and disease control.

Bridging Perspectives: A Multispecialty Roundtable on GLP-1 Receptor Agonists in Psoriasis

Saturday, October 10 • 2:15–3:15 PM PDT • Bandol 2

 Chaired by Joel M. Gelfand, MD, MSCE, FAAD, this CME workshop will explore how glucagon-like peptide-1 (GLP-1) receptor agonists affect the intersection of obesity and psoriasis. Five interactive stations, each led by a different specialist or patient advocate, will share real-world clinical pearls for common provider and patient challenges.

The HCPLive team will provide ongoing coverage from Las Vegas, including session highlights, expert interviews, and key clinical takeaways from the 2026 Fall Clinical Dermatology Conference.

Editor’s note: This summary was created with the help of AI tools.

CMEsquared. Fall Clinical Dermatology Conference 2026. Accessed October 8, 2026. 

https://web.cvent.com/event/cc8afeea-ca2c-46e7-af52-a227f8af567d

CMEsquared. 2026 Fall Clinical Dermatology Conference in-person agenda. Updated September 30, 2026. Accessed October 8, 2026.

Articles

HCPLive previews Fall Clinical 2026 in Las Vegas, October 8-11, with key sessions on atopic dermatitis, psoriasis, and vitiligo, plus expert interviews.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Conference Preview: Fall Clinical Dermatology Conference 2026

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

DBV Technologies announced on September 29, 2026, that it submitted a Biologics License Application (BLA) to the 

for the Viaskin Peanut Patch in children aged 4 to 7 years with 

.¹ The company requested Priority Review, and the FDA previously granted the patch Breakthrough Therapy designation.¹

The filing comes 2 months after Palforzia (peanut allergen powder-dnfp), the only FDA-approved oral immunotherapy (OIT) for peanut allergy, was discontinued on July 31, 2026.

Stallergenes Greer said the discontinuation was not related to product safety, quality, or efficacy. Until the FDA acts on the patch, omalizumab is the only FDA-approved therapy on the market for IgE-mediated food allergy.

This FAQ covers what the BLA includes, how the phase 3 VITESSE trial defined a responder, which patients the data apply to, and how the patch would sit beside omalizumab and office-based OIT.

 The BLA seeks approval of the Viaskin Peanut Patch, an epicutaneous immunotherapy that delivers 250 µg of peanut protein through intact skin, for children aged 4 to 7 years.¹ It is supported by VITESSE, a phase 3, randomized, double-blind, placebo-controlled trial of 654 children at 86 sites in the US, Canada, the UK, Europe, and Australia.

As of October 8, 2026, the FDA has not announced whether it will grant a priority review or a target action date.¹ The patch remains investigational and is not FDA approved for any age group.¹

Children who completed the 12-month double-blind period could enter an open-label extension and receive the patch for up to 3 years in total.¹ Long-term extension data in this age group have not been reported.

Viaskin Peanut Patch BLA Submitted for Peanut Allergy in Children Aged 4-7 Years

. News of the September 2026 BLA filing and priority review request.

Omalizumab Outperforms Multiallergen OIT for Multifood Allergy

. Coverage of the OUtMATCH comparison of omalizumab and multiallergen OIT.

Palforzia Discontinued, Ending Only FDA-Approved Peanut OIT

. Peanut (Arachis hypogaea) Allergen Powder-dnfp (Palforzia) was discontinued on July 31, 2026. HCPLive spoke with Robert Wood, MD, of John Hopkins, and Jacqueline Ross, MD, of Allergy Partners of New Jersey

Q: How did VITESSE define a responder, and what did it show?

At 12 months, 46.6% of children on the patch met responder criteria vs 14.8% on placebo, a difference of 31.8 percentage points (95% CI, 24.5-39.0; 

Response was defined by the eliciting dose (ED) on a double-blind, placebo-controlled food challenge, scaled to each child's baseline:

Baseline ED of ≤ 30 mg peanut protein: 

responder if the 12-month ED reached ≥ 300 mg

 responder if the 12-month ED reached ≥ 600 mg

Q: Which patients would be candidates for the patch?

 The BLA covers children aged 4 to 7 years only.¹ The final label will set eligibility, but the VITESSE population offers the best preview of who the data apply to:

Reaction to ≤ 100 mg of peanut protein on a double-blind, placebo-controlled food challenge

The trial enrolled children with low reaction thresholds, so the results speak most directly to highly sensitive patients in this age range. No BLA has been announced for children younger than 4 years, older children, or adults.¹

The patch is applied daily, and mean compliance in VITESSE was 96.1% in the active group.

That makes it a potential fit for families who want a non-oral, non-injection option that does not require daily ingestion of the allergen.

Q: What does the safety profile look like?

Local application-site reactions drove most adverse events, and treatment-related anaphylaxis occurred in 2 of 438 children (0.5%) on the patch.

 No treatment-related serious adverse events occurred in either group.²

VITESSE Safety Outcomes

Source: VITESSE primary results, Eastern Allergy Conference 2026 poster.

Q: Where do omalizumab and office-based OIT fit while the patch is under review?

 has been FDA approved since February 16, 2024, to reduce allergic reactions, including anaphylaxis, from accidental exposure to 1 or more foods in patients aged ≥ 1 years.

 It is given as an injection with continued food avoidance, and it carries a boxed warning for anaphylaxis.

In stage 1 of the OUtMATCH trial, 67% of children on omalizumab tolerated a single dose of 600 mg or more of peanut protein after 16 to 20 weeks vs 7% on placebo.

Stage 2 of OUtMATCH compared omalizumab with omalizumab-facilitated multiallergen OIT in 117 participants allergic to peanut and ≥ 2 other foods.

 In the intention-to-treat analysis, 36% on omalizumab vs 19% on OIT tolerated ≥ 4044 mg of all 3 foods, with no difference in the per-protocol analysis.

In the OIT group, 31% had serious adverse events, 22% stopped because of adverse events, and 37% needed epinephrine, vs 0%, 0%, and 7% with omalizumab.⁶

 with peanut or peanut flour continues without an FDA-approved product.

It follows standardized protocols, is not FDA approved, and insurance coverage varies.

Age at start matters. In the IMPACT trial of children aged 1 to 3 years, 71% on peanut OIT were desensitized at 134 weeks vs 2% on placebo, and 21% vs 2% met remission criteria after 26 weeks of avoidance, with younger age predicting remission.

Q: How should clinicians weigh the patch, omalizumab, and OIT with families?

The choice turns on how many foods a patient reacts to, the child's age, and how much daily allergen dosing and reaction risk a family can manage.

For families of children aged 4 to 7 who are considering waiting for the patch, there is no FDA decision date yet.¹ For younger children, the IMPACT finding that earlier OIT start predicted remission is worth raising when families ask whether to wait.⁷

 The toddler data could extend the patch to children aged 1 to 3 years, but DBV has not announced a toddler BLA or its timing. Recruitment for COMFORT Toddlers, a supplemental safety study in this age group, closed in the second quarter of 2026.

In the phase 3 EPITOPE trial of 362 children aged 1 to 3 years, 67% on the patch met the primary endpoint vs. 33.5% on placebo (risk difference, 33.4 percentage points; 95% CI, 22.4-44.5).

 Treatment-related anaphylaxis occurred in 1.6% of the patch group and none on placebo.

Responses deepened with longer use. In the open-label extension, 81.3% of children treated for 24 months reached an ED of ≥ 1000 mg, with no treatment-related anaphylaxis in year 2 for that group.⁹ Because early intervention is linked to better outcomes, a toddler indication would bring the patch into the age window that IMPACT linked to higher remission rates with peanut OIT.⁷

This FAQ reflects the regulatory status of the Viaskin Peanut Patch, omalizumab, and peanut oral immunotherapy as of October 8, 2026. The Viaskin Peanut Patch is investigational and not FDA approved, and the FDA has not announced a review classification or action date for the September 2026 BLA. Additional approvals, label changes, or guideline updates are likely, so readers should confirm current status and check the current prescribing information for any approved therapy before relying on this content for clinical decisions.

Derman C. Viaskin Peanut Patch BLA Submitted for Peanut Allergy in Children Aged 4-7 Years. HCPLive. Published October 1, 2026. Accessed October 8, 2026. 

https://www.hcplive.com/view/viaskin-peanut-patch-bla-submitted-peanut-allergy-children-4-7-years

Fleischer DM, Mack DP, Wang J, et al. VITESSE phase 3 trial: efficacy and safety of epicutaneous immunotherapy in children with peanut allergy aged 4 through 7 years. Poster presented at: Eastern Allergy Conference; 2026. Accessed October 8, 2026. 

https://dbv-technologies.com/wp-content/uploads/2026/05/EAC_VITESSE_Primary_Encore_Poster_Print_Ready.pdf

With Palforzia ending, what's next for peanut allergy patients? Allergy & Asthma Network. Accessed October 8, 2026. 

https://allergyasthmanetwork.org/news/palforzia-discontinued/

FDA approves first medication to help reduce allergic reactions to multiple foods after accidental exposure. News release. US Food and Drug Administration. February 16, 2024. Accessed October 8, 2026. 

https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-help-reduce-allergic-reactions-multiple-foods-after-accidental

Wood RA, Togias A, Sicherer SH, et al. Omalizumab for the treatment of multiple food allergies. 

Wood RA, Togias A, Burk CM, et al. Treatment of multifood allergy with omalizumab or multiallergen oral immunotherapy: a randomized clinical trial. 

Jones SM, Kim EH, Nadeau KC, et al. Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study. 

Greenhawt M, Sindher SB, Wang J, et al. Phase 3 trial of epicutaneous immunotherapy in toddlers with peanut allergy. 

Greenhawt M, Albright D, Anvari S, et al. Efficacy and safety of epicutaneous immunotherapy in peanut-allergic toddlers: open-label extension to EPITOPE. 

DBV Technologies reports second quarter and half-year 2026 financial results and business update. News release. DBV Technologies. July 16, 2026. Accessed October 8, 2026. 

Palforzia discontinued, ending only FDA-approved peanut OIT. 

. Published July 31, 2026. Accessed October 8, 2026. 

https://www.hcplive.com/view/palforzia-discontinued-ending-only-fda-approved-peanut-oit

Omalizumab or oral immunotherapy for food allergy, with Robert Wood, MD. 

. Published March 11, 2026. Accessed October 8, 2026. 

https://www.hcplive.com/view/omalizumab-oral-immunotherapy-food-allergy-wood

With the Viaskin Peanut BLA filed for ages 4 to 7, here's where the patch, omalizumab, and office OIT fit for peanut allergy.With the Viaskin Peanut BLA filed for ages 4 to 7, here's where the patch, omalizumab, and office OIT fit for peanut allergy.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Viaskin Peanut Patch FAQ: Where It Fits Beside Omalizumab and OIT 

Sayna Norouzi, MD, is an assistant professor of medicine and clinical nephrologist at Loma Linda University Medical Center

 are diagnosed later than men and are less likely to begin dialysis or receive a kidney transplant, according to a new American Heart Association (AHA) scientific statement published in 

.¹ For women diagnosed young with a rare or autoimmune kidney disease, one of the statement’s co-authors says the burden of CKD begins long before those endpoints.

“This is a topic that is really close to my heart because it’s focused on women’s kidney health. So the fact that we are paying more attention to women’s kidney health and it’s coming from AHA, it’s huge,” Sayna Norouzi, MD, assistant professor of medicine and clinical nephrologist at Loma Linda University Medical Center and director of its Glomerular and Polycystic Kidney Diseases Clinics, said in an interview with 

Family Planning and CKD in Young Women, With Sayna Norouzi, MD

Why CKD Is Diagnosed Later and Treated Less Often in Women

CKD affects about 1 in 10 women worldwide, but the condition may go unrecognized longer in women than in men.¹˒² Kidney function is typically estimated using creatinine, and because women tend to have less muscle mass and produce less creatinine, those estimates may not accurately reflect their kidney function. As a result, some cases are misclassified or caught later.²

That delay carries through to treatment. Women tend to begin dialysis at a lower level of kidney function than men, and globally, men receive kidney transplants about 30% more often than women. In some low and middle income countries, the gap exceeds 10 to 1.² The authors cite caregiving responsibilities, cultural expectations, limited health literacy, and treatment costs as barriers that may keep women from reaching specialist care.²

Female-Specific Risk Factors for CKD Across the Lifespan

The statement frames kidney health as closely tied to reproductive health at every life stage. Preeclampsia and other pregnancy complications may signal greater future risk of kidney disease, heart disease, and stroke, while natural menopause before age 45 and surgical removal of the ovaries before age 50 are each linked with a greater risk of CKD.²

Polycystic ovary syndrome and lupus, which is more common in women than men, are also associated with greater CKD risk. Among people with diabetes, the leading cause of CKD worldwide, some evidence suggests women may progress to kidney failure at higher rates than men.²

Family Planning After an IgA Nephropathy or Lupus Nephritis Diagnosis

For Norouzi, the women most affected by these gaps are often those with glomerular and autoimmune kidney diseases. Patients with IgA nephropathy or lupus nephritis are frequently diagnosed young, she said, which means the effects of CKD extend well beyond eventual dialysis or transplant and shape how they navigate life from the point of diagnosis.

In her clinic, which includes patients with lupus nephritis, IgA nephropathy, and C3 glomerulopathy, those concerns surface almost immediately. “The moment we talk about chronic kidney disease, they’re going to ask questions about how they’re going to have a family, if they can get pregnant, if they can have kids,” she said. Patients also ask whether they should get married and whether to tell a partner about their diagnosis, Norouzi added, questions that lead her to wonder whether clinicians are paying enough attention to the burden of CKD in women.

The statement supports bringing those conversations into routine care. Pregnancy in women with CKD may increase the risk of disease progression and pregnancy complications, and managing blood pressure, blood sugar, and body weight is suggested for women with CKD planning a pregnancy. The authors recommend embedding reproductive health assessment into CKD care as a step toward more precise kidney medicine.²

Closing the Evidence Gap for Women With CKD

Women remain underrepresented in CKD trials, and few studies report results by sex, which limits how well the evidence applies to women.³ Women may also respond differently to kidney therapies because of differences in how drugs are absorbed, distributed, metabolized, and cleared.² The statement calls for enrolling enough women in trials to detect differences in treatment effects, reporting results by sex and reproductive health factors, and studying sex-specific pharmacokinetics and pharmacodynamics to guide dosing and drug selection.²˒³

For Norouzi, better evidence needs to translate into better support for patients over the long term.

“Yes, there are endpoints of ending up on dialysis and transplant, but how getting diagnosed with CKD is going to affect their life choices, and how they’re going to navigate life after being diagnosed with rare disease and CKD at such a young age, that’s something that we should pay more attention to and come up with better solutions for our patients on how to navigate CKD and complications throughout life,” she said.

Editors’ note: Norouzi reports relevant disclosures with Calliditas, Travere, Apellis and others.

Gohar EY, Shah S, Oh ES, et al. Women’s kidney health in focus: a scientific statement from the American Heart Association. 

. Published online September 17, 2026. doi:10.1161/CIR.0000000000001471

American Heart Association. Women’s kidney health may be overlooked, delaying critical prevention and treatment opportunities. News release. September 17, 2026. Accessed October 8, 2026. 

https://newsroom.heart.org/news/womens-kidney-health-may-be-overlooked-delaying-critical-prevention-and-treatment-opportunities

American Heart Association. Women’s kidney health in focus. Science News. September 17, 2026. Accessed October 8, 2026. 

https://professional.heart.org/en/science-news/womens-kidney-health-in-focus

Videos

An AHA statement co-author says reproductive and family planning concerns belong in kidney care for women with glomerular disease.

Chronic Kidney Disease

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

How Glomerular Disease Shapes Young Women's Life Choices, With Sayna Norouzi, MD

Eric Simpson, MD, MCR, of the Department of Dermatology at Oregon Health & Science University in Portland.

Tilrekimig (PF-07275315), an investigational trispecific antibody against interleukin (IL)-4, IL-13, and thymic stromal lymphopoietin (TSLP), achieved EASI-75 in up to 63% of biologic-naive adults with moderate to severe 

 at week 16 in phase 2 data presented at the 

European Academy of Dermatology and Venereology (EADV) Congress 2026

The molecule pairs the IL-4/IL-13 pathway blockade of dupilumab (Dupixent) with inhibition of TSLP, an upstream target already validated in asthma.¹ Pfizer has since moved tilrekimig into phase 3 development in atopic dermatitis, including a trial with dupilumab as an active comparator.

“It's a trispecific molecule, so it binds 3 different cytokines at the same time," said Eric Simpson, MD, MCR, of the department of dermatology at Oregon Health & Science University, in Portland. "I think this is the first time we've seen public data of a bispecific or trispecific in atopic dermatitis."

Tilrekimig Meets EASI-75 Goal in Atopic Dermatitis, With Eric Simpson, MD

Simpson, the study's lead author, spoke with HCPLive at the congress about the interim findings, the gap between skin-clearance endpoints, and what remains unknown ahead of larger trials.

Tilrekimig EASI-75 Response and Dose Findings at Week 16

The ongoing randomized, double-blind, placebo-controlled phase 2 trial enrolled biologic-naive adults with moderate to severe atopic dermatitis and a baseline EASI score of ≥ 16.¹ In stage 1, patients received subcutaneous tilrekimig 450 mg (n = 41) or placebo (n = 20) every 2 weeks. In stage 2, patients received tilrekimig 400 mg (n = 41), 200 mg (n = 41), 50 mg (n = 23), or placebo (n = 22) every 4 weeks through week 16.¹

The primary endpoint was the proportion of patients achieving EASI-75 at week 16. In stage 1, 63% of patients receiving tilrekimig 450 mg achieved EASI-75 compared with 20% receiving placebo (treatment difference, 43%; 

 =.0008).¹ In stage 2, EASI-75 rates reached 59%, 61%, and 48% with the 400 mg, 200 mg, and 50 mg doses, respectively, versus 9% with placebo (treatment differences, 50%, 52%, and 39%; all 

Simpson described a partial dose response across the monthly regimens. The 2 top doses produced the strongest and most similar efficacy, and the 50 mg dose trailed both, he said.

Placebo-Adjusted vIGA and Tilrekimig Safety Profile


Tilrekimig (PF-07275315) is an investigational trispecific antibody from Pfizer targeting IL-4, IL-13, and TSLP. It is not approved by any regulatory authority.

What did the tilrekimig phase 2 trial show?


At week 16, 48% to 63% of biologic-naive adults receiving tilrekimig achieved EASI-75, compared with 9% to 20% receiving placebo, meeting the primary endpoint at every dose.


No conjunctivitis signal emerged through 16 weeks, according to Simpson, though larger and longer trials are needed to confirm the finding.

For the key secondary endpoint of a validated Investigator's Global Assessment (vIGA) score of 0/1 with ≥ a 2-point improvement, 30% of stage 1 patients receiving tilrekimig responded versus 12% with placebo (

 =.0251).¹ Across stage 2 dose groups, 26% to 27% of patients achieved vIGA 0/1 versus 0% with placebo (all 

Simpson acknowledged the vIGA response rates fell well below the EASI-75 results at every dose. He encouraged clinicians to focus on the placebo-adjusted effect size, noting the placebo-adjusted vIGA delta did not necessarily exceed those of currently available biologics, though trial populations differ. Whether additional dosing could widen the delta remains an open question, he said.

In an exploratory analysis, 43% and 51% of patients receiving the 400 mg and 200 mg monthly doses achieved ≥ a 4-point reduction in the weekly average Peak Pruritus Numerical Rating Scale (PP-NRS) score, compared with 7% with placebo.¹ Tilrekimig was well tolerated, with no dose-dependent safety signals and an adverse event frequency comparable to placebo.¹

No conjunctivitis signal emerged in the study, a departure from the dupilumab experience, according to Simpson. If larger trials confirm the finding, it could suggest TSLP blockade offers some protective effect, he said.

"It's always important to look at safety with a new mechanism of action," said Simpson. "Those targets are validated in atopic dermatitis and seem safe."

Editor’s note: Reported disclosures for Simpson include GENZYME CORPORATION, PFIZER INC., Roche Products Limited, Regeneron Pharmaceuticals, Inc., Galderma Laboratories, L.P., Amgen Inc., LEO Pharma Inc., Janssen Biotech, Inc., Incyte Corporation, Hoffmann-La Roche Limited, Organon LLC, and Janssen Biotech, Inc.

Simpson E, Tan J, Paller A, et al. Phase 2 study of novel trispecific tilrekimig (PF-07275315) in patients with moderate-severe atopic dermatitis: interim efficacy and safety results at 16 weeks. Abstract 1730. Presented at: EADV Congress 2026; September 30–October 3, 2026; Vienna, Austria.

Campbell P. EADV 2026: tilrekimig achieves EASI-75 across all doses in atopic dermatitis. HCPLive. Published October 1, 2026. Accessed October 8, 2026. 

https://www.hcplive.com/view/eadv-2026-tilrekimig-achieves-easi-75-across-all-doses-in-atopic-dermatitis

Pfizer. Pfizer's tilrekimig shows significant skin clearance in phase 2 atopic dermatitis study. Published October 1, 2026. Accessed October 8, 2026. 

https://www.businesswire.com/news/home/20260930032966/en/

Simpson discusses 16-week phase 2 data on the IL-4/IL-13/TSLP trispecific, including vIGA gaps and conjunctivitis findings.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Jacquelyn M. Powers, MD, MS, is section chief of hematology at Texas Children's Hospital and associate professor in the department of pediatrics at Baylor College of Medicine. She chaired the ASH panel that wrote the iron deficiency diagnosis guidelines.

She is an expert in the management of iron deficiency anemia, with expertise in both oral iron supplementation and the indications for and use of intravenous iron therapy. Her research aims to better identify patients at risk for iron deficiency and find the most successful treatment approach for children and adolescents with iron deficiency anemia. She is particularly interested in patient-centered outcomes such as fatigue and quality of life in children treated with oral or intravenous iron. 

She also served as a lead author of a revised American Academy of Pediatrics (AAP) clinical report, published in the July 2026 issue of Pediatrics, which was the first major update to pediatric iron deficiency guidance in nearly a decade

Jacquelyn Powers, MD, MS.png

The guideline chair answers key questions on new ferritin cutoffs, symptoms without anemia, inflammation, and lab reporting.

Latest News

Conference Preview: Fall Clinical Dermatology Conference 2026

Viaskin Peanut Patch FAQ: Where It Fits Beside Omalizumab and OIT

How Glomerular Disease Shapes Young Women's Life Choices, With Sayna Norouzi, MD

Tilrekimig Meets EASI-75 Goal in Atopic Dermatitis, With Eric Simpson, MD

FAQ: ASH's New Ferritin Thresholds, With Jacquelyn Powers, MD, MS